Adjuvant Dabrafenib Plus Trametinib Deemed Promising for Stage IIIA Melanoma
Source: Cancer Therapy Advisor, April 2025
Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma, according to retrospective findings published in Annals of Oncology.
Researchers noted that these findings do not confirm the superiority of dabrafenib and trametinib, given the retrospective nature of the study, but the combination “appears promising” in this setting.
This study included 628 patients with stage IIIA cutaneous melanoma who were diagnosed between January 1, 2018, and July 1, 2021, at cancer centers in Australia, Europe, and the United States. The patients had received no adjuvant treatment (n=292), adjuvant pembrolizumab or nivolumab (n=256), or adjuvant dabrafenib plus trametinib (n=80).